Products for Research Use Only
RegisterLogin

Icovamenib

CAT: 0804-HY-150105-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-150105-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes[1][2][3][4][5].
CAS Number
2448172-22-1
Product Name Alternative
BMF-219; Menin-MLL inhibitor 21
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/menin-mll-inhibitor-21.html
Purity
98.96
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(CN2C[C@@H](CCC2)NC(C=C)=O)=CC=N1)NC3=CC=C(C=C3)C4=CC5=C(N6CCOCC6)N=CN=C5N4
Molecular Formula
C31H34N8O3
Molecular Weight
566.65
References & Citations
[1]Thomas Butler, et al. Irreversible inhibitors of menin-mll interaction.WO2020142557 A1.|[2]Jeffrey Lancet MD, et al. Dovalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL) : Preliminary Phase 1 Data from the Covalent-101 Study. Blood. Volume 142, Supplement 1, 2 November 2023, Page 2916. |[3]Mo J, et al. Design, synthesis, and evaluation of Menin-targeting compounds for the treatment of acute Myelocytic leukemia (AML) . Eur J Med Chem. 2025 Jun 12;296:117847.|[4]Mini Balakrishnan, et al., Combination of Icovamenib and GLP-1-based Therapeutic Agents Improves Beta Cell Function and Insulin Secretion. Metabolism - Clinical and Experimental, Volume 168, 156226.|[5]Carraway, H. E., et al., (2025) . Complete remission of NUP98 fusion-positive acute myeloid leukemia with the covalent menin inhibitor BMF-219, icovamenib. Haematologica, 110 (4), 1041–1046.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Popular Products